News
Merck, a leading science and technology company, today announced the presentation of detailed results from Cohort B of the global Phase 2 WILLOW study (NCT05162586) evaluating enpatoran, an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback